Pharmacy Operational Update
MedPal AI plc reported a record month in March 2026, dispensing 41,600 prescription items, a 27.5% increase month-on-month, bringing the total dispensed since launch to approximately 200,000. Pharmacy operations now generate an annualised turnover exceeding £5 million, with a gross margin above 34% in March, demonstrating the operational leverage of its automated platform. The company anticipates continued growth driven by expanding NHS volumes, momentum in its MedPal.clinic for weight-loss treatments, and substantial capacity within its dispensing infrastructure.
Select text to share a quote on X · sign in to keep highlights & notes in your MPAL notes
MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, is pleased to announce a record month of pharmacy dispensing activity at its wholly owned subsidiary, MedPal Limited.
Highlights:
- Record month: 41,600 prescription items dispensed in March 2026, the highest monthly volume since operations commenced, representing growth of 27.5% month-on-month
- Zero to scale in five months: Dispensing volumes have grown from zero in October 2025 to over 41,600 items in March 2026, demonstrating rapid scaling of the Company's automated pharmacy platform
- Cumulative milestone: Total items dispensed since launch has now reached approximately 200,000, underscoring sustained adoption of the Company's NHS and private pharmacy services
- Annualised revenue: Pharmacy operations now exceed £5 million in annualised turnover based on March 2026 dispensing volumes
- Strong margins: Gross margin for March 2026 exceeded 34%, reflecting the operational leverage of the Company's automated dispensing infrastructure as volumes scale
The continued acceleration in dispensing volume demonstrates the increase in patient demand across both NHS Distance Selling Pharmacy services and private prescriptions through MedPal.clinic. The Company's technology-led cost structure continues to support strong gross margins, which in March 2026 exceeded 34%. The Directors believe that the platform has substantial capacity for further volume growth, which will deliver meaningful operating leverage as fixed costs are absorbed over a larger revenue base.
Outlook
The Board remains highly confident in the Company's growth trajectory and the significant market opportunity ahead. Key drivers of continued pharmacy growth include:
- Expanding NHS volumes: Growing patient adoption of the Company's Distance Selling Pharmacy services, supported by 24/7 automated robotic dispensing and rapid nationwide delivery
- MedPal.clinic momentum: Continued strong demand for GLP-1 weight-loss treatments, with MedPal.clinic's AI-powered triage and zero-cost consultation model providing a significant competitive advantage in a rapidly expanding UK obesity market
- Operational capacity: Substantial headroom within the Company's robotic dispensing infrastructure to accommodate significantly higher volumes without proportionate cost increases, providing a clear pathway to improved profitability
Jason Drummond, Chief Executive Officer of MedPal AI, commented:
"Dispatching over 41,000 items in March, our highest ever monthly total, is a landmark moment. In just five months, we have scaled from zero to an annualised pharmacy revenue run rate exceeding £5 million, and we have done this while delivering a gross margin of over 34% in March. This extraordinary rate of growth demonstrates the power of our vertically integrated, AI-driven model.
"Our technology-led cost structure means that as dispensing volumes grow, fixed costs are spread over a larger revenue base, driving further margin improvement. The traditional pharmacy model is being disrupted, and MedPal is leading that disruption. We look forward to updating the market on continued progress."
The Directors of the Company are responsible for the contents of this announcement.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.